The historical rank and industry rank for Can Fite Biopharma's OCF Margin % or its related term are showing as below:
XTAE:CANF'
s OCF Margin % Range Over the Past 10 Years
Min: -5281.39 Med: -1146.5 Max: -108.77
Current: -2208.41
During the past 13 years, the highest OCF Margin % of Can Fite Biopharma was -108.77%. The lowest was -5281.39%. And the median was -1146.50%.
XTAE:CANF's OCF Margin % is ranked worse than 85.4% of 959
companies
in the Biotechnology industry
Industry Median: -66.52
vs XTAE:CANF: -2208.41
Can Fite Biopharma OCF Margin % Related Terms
Can Fite Biopharma OCF Margin % Historical Data
* Premium members only.
The historical data trend for Can Fite Biopharma's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTAE:CANF vs VRTX, REGN, ALNY: OCF Margin % Comparison
For the Biotechnology subindustry, Can Fite Biopharma's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Can Fite Biopharma OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Can Fite Biopharma's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Can Fite Biopharma's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Can Fite Biopharma (XTAE:CANF) has a OCF Margin % of -2,066.28% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Can Fite Biopharma and its competitors. According to the industry distribution chart, Can Fite Biopharma ranks #819 out of 959 companies in the Biotechnology industry, placing it in the top 85.4%.
Is Can Fite Biopharma's OCF Margin % too high?
Can Fite Biopharma's current OCF Margin % is -2,066.28%. Based on the distribution chart, Can Fite Biopharma ranks #819 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Can Fite Biopharma has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Can Fite Biopharma's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Can Fite Biopharma ranks #819 out of 959 companies for OCF Margin %. This places Can Fite Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Can Fite Biopharma and its competitors. Can Fite Biopharma's current OCF Margin % is -2,066.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Can Fite Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Can Fite Biopharma (XTAE:CANF) is currently considered Possible Value Trap. The stock's GF Value™ is ₪9.51, compared to a current price of ₪4.75 — trading 50% below its estimated fair value. The current OCF Margin % is -2,066.28%. Can Fite Biopharma's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Can Fite Biopharma (XTAE:CANF), the current OCF Margin % is -2,066.28% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Can Fite Biopharma (XTAE:CANF) Overvalued in 2026?
Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be undervalued.
The current stock price of ₪4.75 is trading 50% below its estimated GF Value™ of ₪9.51.
GuruFocus considers Can Fite Biopharma to be Possible Value Trap.
Key valuation signals for XTAE:CANF:
OCF Margin %: -2,066.28%
GF Value™: ₪9.51 vs. price of ₪4.75 (50% below fair value)
No single metric tells the full story. See the XTAE:CANF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
58GF Score
Get the complete analysis for XTAE:CANF
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:CANF has been successfully added to your 
